Slide 1: Clinical Value and Roadmap
www.viewray.com Clinical Value and Roadmap September 10, 2021 Exhibit 99.1
Slide 2: Forward-looking statements disclaimer
This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise, references to “ViewRay,” “the company,” “w
Slide 3: Our mission: Treat and prove what others can’t
Our mission: Treat and prove what others can’t. ©2021 ViewRay Technologies, Inc. All rights reserved. Approved for External (Investor) Distribution.
Slide 4: Customers’ Definition of Clinical Success
Customers’ Definition of Clinical Success MRIdian SMART: Stereotactic MR-guided Adaptive Radiotherapy Among alternatives in the clinical landscape, we have found only MRIdian’s evidence fits this criteria. Ablative Dose Tight Margins No Fiducials No or Low Grade 3 Toxicity 1 2 3 5 5 or Fewer Fractio
Slide 5: Focused-Beachhead Patient-Centric Roadmap
Focused-Beachhead Patient-Centric Roadmap Bone #1 #2 #3 #4 Expand utilization of MRIdian SMART Become first line therapy PANCREAS PROSTATE LUNG BRAIN GI GU Thoracic Cranial ©2021 ViewRay Technologies, Inc. All rights reserved. Approved for External (Investor) Distribution.
Slide 6: Prospective studies and clinical trial program
Prospective studies. Larger ‘N’ Confirm signals in key tumor sites Safety and Efficacy endpoints Randomized controlled trials Comparative Safety and efficacy endpoints 60+ investigator-initiated trials Feasibility Explore new indications/expand SMART Reduce fx and improve workflow MIRAGE (CT vs. MRI
Slide 7: Pancreas: extending MRIdian SMART as alternative to surgery
Demonstrate MRIdian SMART ability to treat inoperable Extend MRIdian SMART across disease spectrum of pancreatic cancer Move MRIdian SMART towards alternative to surgery Pancreas1 Safely extend patient life. ASTRO 2021 Multicenter retrospective 3 centers, 148 patients Toxicity and Survival SMART Pan
Slide 8: Prostate: move to front-line radiation therapy option
Move to front-line radiation therapy option Extend MRIdian SMART into post-operative setting Redefine standard course of treatment Prostate1 Improve patient quality of life. Signal MIRAGE RCT Demonstrate superior safety of MRIdian SMART vs CBCT SBRT for intact prostate 300 patients; single center (U
Slide 9: Lung: demonstrate safety of MRIdian SMART
Demonstrate safety of MRIdian SMART to treat what others cannot Lung1 Safe treatment with curative intent. Lung STAAR: Prove safe MRIdian SMART in tough to treat tumors in patients with few options Multicenter single arm 60 patients Toxicity Local control and survival Start up phase FUTURE MRIDIAN T
Slide 10: Customers are purchasing multiple MRIdian systems
Customers are purchasing multiple MRIdian systems = Top and bottom line impact for customers + MRIdian 51 Clinical Strategic Economic MRIdian Value Chain MRIdian SMART ©2021 ViewRay Technologies, Inc. All rights reserved. Approved for External (Investor) Distribution.
Slide 11: Value: physician testimonial
Value …allows you to treat patients whom you could never have treated before. The MRIdian changes your practice; it changes who you look at as a candidate for radiation therapy. Patrick Kelly, M.D. Ph.D Department of Radiation Oncology Orlando Health UF Health Cancer Center “ “ ©2021 ViewRay Technol
Slide 12: ViewRay | Visibly Better
@ VIEW RAY |VISIBLY BETTER
Slide 13: Presentation Citations
Presentation Citations Slide 3 Internal and historical company data MRIdian usage data as of June 30, 2021 Slide 4 Ablative dose, Tight margins, No fiducials: Chuong MD, Bryant J, Mittauer KE, Hall M, Kotecha R, Alvarez D, Romaguera T, Rubens M, Adamson S, Godley A, Mishra V, Luciani G, Gutierrez AN
Slide 14: Presentation Citations (continued)
Slide 7 - Rudra S. et al. (2019). Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Medicine, 8(5), 2123-2132; Finazzi, et al. Role of on-table plan adaptation in MR-guided ablative radiation therapy for central lung tumors. Int J
Slide 15: Presentation Citations (continued)
Slide 10 1. - Henke, L., et al. (2018). Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiotherapy and Oncology, 126(3), 519-526; Henke LE, et al. Stereotactic mr-guided onli